Literature DB >> 1833664

Measurement of caudate nucleus area--a more accurate measurement for Huntington's disease?

J M Wardlaw1, R J Sellar, L J Abernethy.   

Abstract

Caudate nucleus atrophy occurs in Huntington's disease and methods of measuring this have been described using axial CT, but these are indirect and lack sensitivity. We measured caudate nucleus area (blind to the subjects' clinical state) in 30 subjects with or at risk of Huntington's disease, and in 100 normal age matched controls. Fifteen subjects with established symptomatic Huntington's disease, 3 with early symptoms, and 3 presymptomatic subjects (2 showing a high probability for the Huntington's disease gene on genetic testing, and one who has since developed symptoms) were correctly identified. Three normal (gene negative) family members were also correctly identified. Outcome is awaited in 6. CT caudate area measurement is simple and reproducible and we have found it to be a useful confirmatory test for Huntington's disease.

Entities:  

Mesh:

Year:  1991        PMID: 1833664     DOI: 10.1007/bf00587814

Source DB:  PubMed          Journal:  Neuroradiology        ISSN: 0028-3940            Impact factor:   2.804


  15 in total

1.  Computed tomography for Huntington's disease.

Authors:  C F Terrence; J F Delaney; M C Alberts
Journal:  Neuroradiology       Date:  1977-06-27       Impact factor: 2.804

2.  Presymptomatic testing for Huntington chorea: guidelines for moral and social accountability.

Authors:  J F Smurl; D D Weaver
Journal:  Am J Med Genet       Date:  1987-02

3.  Toward quantitative characterization of the caudate nucleus through CT image enhancement.

Authors:  R A Stein; K I Pearce; J Nosil; T C Strecker
Journal:  J Comput Assist Tomogr       Date:  1985 Jul-Aug       Impact factor: 1.826

4.  The measurement of abnormal movement: methods developed for Huntington's disease.

Authors:  S E Folstein; B Jensen; R J Leigh; M F Folstein
Journal:  Neurobehav Toxicol Teratol       Date:  1983 Nov-Dec

5.  Neuropathological classification of Huntington's disease.

Authors:  J P Vonsattel; R H Myers; T J Stevens; R J Ferrante; E D Bird; E P Richardson
Journal:  J Neuropathol Exp Neurol       Date:  1985-11       Impact factor: 3.685

6.  Late onset of Huntington's disease.

Authors:  R H Myers; D S Sax; M Schoenfeld; E D Bird; P A Wolf; J P Vonsattel; R F White; J B Martin
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-06       Impact factor: 10.154

7.  The combined use of positron emission tomography and DNA polymorphisms for preclinical detection of Huntington's disease.

Authors:  M R Hayden; J Hewitt; A J Stoessl; C Clark; W Ammann; W R Martin
Journal:  Neurology       Date:  1987-09       Impact factor: 9.910

8.  Decreased iodine-123 IMP caudate nucleus uptake in patients with Huntington's disease.

Authors:  J S Nagel; K A Johnson; M Ichise; R J English; T M Walshe; J H Morris; B L Holman
Journal:  Clin Nucl Med       Date:  1988-07       Impact factor: 7.794

9.  Morphometric demonstration of atrophic changes in the cerebral cortex, white matter, and neostriatum in Huntington's disease.

Authors:  S M de la Monte; J P Vonsattel; E P Richardson
Journal:  J Neuropathol Exp Neurol       Date:  1988-09       Impact factor: 3.685

10.  Positron emission tomographic scan investigations of Huntington's disease: cerebral metabolic correlates of cognitive function.

Authors:  S Berent; B Giordani; S Lehtinen; D Markel; J B Penney; H A Buchtel; S Starosta-Rubinstein; R Hichwa; A B Young
Journal:  Ann Neurol       Date:  1988-06       Impact factor: 10.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.